New therapeutic agents in the management of HIV: An overview of darunavir for clinicians

Sexual Health

Volumn 5, Issue 3, 2008, Pages 235-241

  Rotty, Jessica ^a   Hoy, Jennifer ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Drug resistance; HAART; Prezista; Protease inhibitor

Indexed keywords

ABACAVIR; ATAZANAVIR; ATORVASTATIN; CLARITHROMYCIN; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; METHADONE; NEVIRAPINE; OMEPRAZOLE; PRAVASTATIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RANITIDINE; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VIRUS RNA; WARFARIN; ZIDOVUDINE;

ABDOMINAL PAIN; BLEEDING; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFORMATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOCYTE COUNT; LIPODYSTROPHY; NAUSEA; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL COMPETENCE; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; SULFONAMIDES; VIRAL LOAD;

EID: 49449119140     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH08005     Document Type: Review

References (24)

1. Busse KHS, Penzak SR. Darunavir: a second-generation protease inhibitor. Am J Health Syst Pharm 2007; 64: 1593-602. doi: 10.2146/ajhp060668
2. Katlama C, Esposito R, Gatell JM, Goffard J-C, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21: 395-402. doi: 10.1097/QAD.0b013e328013d9d7
3. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007; 21: F11-8. doi: 10.1097/QAD.0b013e3280b07b47
4. Molina JM, Cohen C, Katlama C, Grinszstein B, Timerman A, de Jesus PR, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients. J Acquir Immune Defic Syndr 2007; 46: 24-31.
5. Clotet B, Bellos N, Molina J-M, Cooper D, Goffard J-C, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78. doi: 10.1016/S0140-6736(07)60497-8
6. Madruga JV, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 49-58. doi: 10.1016/S0140-6736(07)61049-6
7. DeJesus E, Ortiz R, Khanlou H, Voronin E, Van Luzen J, Andrade-Villanueva J, et al. Efficacy and safety of darunavir/ritonavir vs lopinavir/ritonavir in ARV treatment naive HIV-1-infected patients at week 48: ARTEMIS. Proceedings of the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, Illinois, USA.
8. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 39-48. doi: 10.1016/S0140-6736(07)61048-4
9. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370: 29-38. doi: 10.1016/S0140-6736(07)61047-2
10. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49: 2314-21. doi: 10.1128/AAC.49.6.2314-2321.2005
11. Collier ACGJ, Katner HP, Rozembaum W, Vangeneugden T, Lefebvre E. Safety and efficacy of TMC114/r (darunavir/ritonavir) by gender, age and race: combined 24-week analysis of POWER 1, 2 and 3. Program and abstract of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy 2006; San Francisco, California, USA. Abstract H-1396.
12. Prezista Product Information. December 2007; Prezista USA Product Information available online at: http://www.prezista.com/docs/us_package_insert. pdf [verified December 2007].
13. Sekar V, Kestens D, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 2007; 47: 479-84. doi: 10.1177/0091270006298603
14. Sekar VJ, Lefebvre E, De Marez T, Spinosa-Guzman S, De Pauw M, De Paepe E, et al. Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers. Drugs R D 2007; 8: 241-8. doi: 10.2165/00126839-200708040-00004
15. Scholler-Gyure M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther 2007; 12: 789-96.
16. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15: 119-25.
17. De Meyer S, De Paepe E, Vangeneugden T, Van Baelen B, Spinosa-Guzman S, Lefebvre E, et al. Effect of baseline and on-treatment mutations on the antiviral activity of darunavir/ritonavir and lopinavir/ritonavir: results of a randomised, controlled, phase III study (TITAN). Proceedings of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007: Sydney, Australia. Abstract WEPEB038.
18. Haubrich R. Defining HIV susceptibility to new antiretroviral agents-darunavir. J Infect Dis 2007; 196: 1125-7. doi: 10.1086/521631
19. Mitsuya Y, Liu TF, Rhee S-Y, Fessel WJ, Shafer RW. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007; 196: 1177-9. doi: 10.1086/521624
20. DeMeyer S, Dierynck I, Lathouwers E, VanBaelen B, Vangeneugden T, Spinoso-Guzman S, et al. Identification of mutations predictive of a diminished response to darunavir/ritonavir: analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2. Presentedat the 6th European HIV Drug Resistance Workshop, Budapest, Hungary, 26-28 March 2008.
21. De Meyer S, Vangeneugden T, Lefebvre E, Van Marck H, Azijn H, De Baere I, et al. Phenotypic and genotypic determination of resistance to TMC114: pooled analysis of POWER 1, 2, and 3. Proceedings of the 8th International Congress on Drug Therapy in HIV Infection; 2006; Glasgow, Scotland. Abstract P196.
22. Coakley E, Benhamida J, Picchio G, de Bethune MP. Defining the upper and lower phenotypic clinical cut-offs for darunavir/ritonavir by the PhenoSense assay. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA. Poster 160.
23. Parkin N, Stawiski E , Chappey C, Coakley E. Darunavir/amprenavir cross-resistance in clinical samples submitted for phenotype/genotype combination resistance testing. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles, California, USA. Poster 607.
24. Sekar V, De Meyer S, Vangeneugden T, Lefebvre E, De Pauw M, Van Baelen E, et al. Absence of darunavir exposure-efficacy and exposure-safety relationships in POWER 3. AIDS 2006 - Proceedings of the 16th International AIDS Conference; 2006; Toronto, Canada. Abstract TUPE0078.